2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Vesugen (also called vezugen) is a bioregulatory tripeptide with the amino sequence Lys-Glu-Asp [1], [2], developed based on the primary structure of polypeptides from animal organs. It was discovered at the Military Medical Academy in Russia alongside other anti-aging peptides like Epitalamin and Cortexin in Vladimir Khavinson’s group [3].
Vesugen may deliver vasoprotective and geroprotective benefits through epigenetic regulation of aging-related proteins, including:
A clinical studied treated 32 people aged 41-83 years with polymorbidity and organic brain syndrome in remission with vesugen. This treatment significantly slowed the rate of aging based on biological age indicators. Importantly, there were no changes in the degree of chromatin condensation, leading the authors to declare it safe on a nuclear genetic level [8].
Even though vesugen doesn’t have direct antioxidant activity, it can modify the structure of human lipoproteins and restrict lipid peroxidation [1]. On the other hand, a more recent study [8] performed on human subjects showed that Vesugen had pro-oxidant activity and the authors recommended against its use as an antioxidant.
A 2008 study suggests that short regulatory peptides, including vesugen, decrease the percentage of dead cells in the neuronal population [1].
An important clinical trial done on 150 truck drivers affected by occupational factors demonstrated that administration of short bioregulating peptides which included vesugen restored psychoemotional status and enhanced stress resistance [9].
Moreover, in the mouse model of Alzheimer’s disease, a pronounced improvement in synaptic dendritic structures after administration of vesugen suggests that it may be able to restore neuroplasticity during early stages of Alzheimer’s disease [2].
Atherosclerosis is a vascular disease characterized by lipid accumulation and plaque formation within arterial walls, resulting from endothelial injury associated with aging and oxidative stress. As arterial stiffening and narrowing from atherosclerotic plaque increase vascular resistance, hypertensive disorder may develop, which in turn further promotes endothelial damage and plaque progression [10].
Moreover, in vitro studies suggest that vesugen modulates endothelin-1 expression, potentially normalizing its levels and mitigating atherosclerotic and restenotic changes [6].
Vesugen was also investigated in 41 patients with vasculogenic erectile dysfunction as a manifestation of atherosclerosis. Clinical and instrumental parameters of blood flow in the main penile arteries before and after therapy showed that the blood flow through the main artery of the penis significantly improved [11].
Even though vesugen had no effect on differentiation capacity of immune cells of the pineal gland, it enhanced their proliferation potential [12]. In addition, Vesugen increased proliferative activity of thymocytes and activated their differentiation into regulatory T cells, preventing their apoptosis [7]. Since age-related reduction of thymus functional activity is an important cause of infections, vesugen could be of great benefit in boosting immunity.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Vesugen is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
In an in vitro molecular docking study, Lys-Glu-Asp was shown to regulate the 5-tryptophan hydroxylase gene, which encodes the enzyme involved in serotonin synthesis. The same in vitro work proposes that Lys-Glu-Asp epigenetically regulates serotonin synthesis in the brain cortex, which the authors say indicates neuro- and geroprotective activities.
In a clinical trial in elderly human participants with functional central nervous system disorders, oral application of KED (Lys-Glu-Asp) was reported to improve memory and attention. In honey bees, Lys-Glu-Asp was found to modulate associative learning in models of short-term and long-term memory.
Vesugen, which is also called Lys-Glu-Asp (KED), was studied in cultured human periodontal ligament stem cells (hPDLSCs) for its effect on neuronal differentiation using immunofluorescence and western blot analysis. In these in vitro studies, the compound of peptides AEDG, KE, AED and KED was reported to promote neuronal differentiation of hPDLSCs, with KED being one of the four peptides in that compound. In hPDLSCs cultures, KED increased the expression of Nestin, a neurofilament protein expressed in early neuronal precursors.
The cited studies examined the KED peptide, and the facts do not state what they found for the compound sold here. In a review of published reports and the authors' own experimental findings, the KED peptide was suggested to regulate the expression of genes of cell aging and apoptosis, including p16 and p21. In an in vitro study, the geroprotective effect of the KED peptide was described as being realized by increasing sirtuin1 expression, which takes part in DNA reparation.
In hypophysectomized birds, the Lys-Glu-Asp-Gly tetrapeptide significantly prevented thyroid impairments. Its protective effect was associated with increased levels of TSH, T3 and T4. In these animal studies, restoration of thyroid function and morphology after Lys-Glu-Asp-Gly treatment was greater in one-year-old chickens than in five-year-old chickens.
In vitro, adsorption of the H-Lys-Glu-Asp-Gly-OH form (KEDG) on copper in sodium chloride solution was best fitted to the Freundlich adsorption isotherm. Post-corrosion scanning electron microscopy of copper in vitro, in the presence of the H-Lys-Glu-Asp-Gly-OH form (KEDG), showed a network surface morphology with microdeposits of acicular appearance. Energy-dispersive analysis of that copper surface in vitro found an upper layer containing the H-Lys-Glu-Asp-Gly-OH form (KEDG), sodium chloride and copper corrosion compounds.
A review describes hepatoprotective, immunoprotective and antiageing properties of the KEDA tetrapeptide (Lys-Glu-Asp-Ala, also called Livagen) and of the liver polypeptide complex Ventvil. In experimental liver pathology models of liver fibrosis and acute and chronic hepatitis, studied in animals and in vitro, the Lys-Glu-Asp-Ala form (KEDA peptide) showed high efficiency, as did Ventvil.
In cell cultures, the peptides under study, including Lys-Glu-Asp, stimulated proliferative and antiapoptotic activity of mature regulatory T cells. In cell cultures, Lys-Glu-Asp induced expression of the low-differentiated lymphocyte marker CD5 and the macrophage marker CD68. In these cultures, this effect on CD5 and CD68 was less pronounced in old cultures than in young ones.
In organotypic culture of pineal glands from 3-month-old rats, Lys-Glu-Asp stimulated the expression of the proliferative protein Ki-67. In the same rat pineal gland culture system, Lys-Glu-Asp did not affect the expression of the apoptosis marker AIF.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.